NASDAQ · DCTH
Healthcare · Medical - Devices
$16.39
Down-$0.10 (-0.58%)
Updated Aug 28, 2026, 3:59 PM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
DCTH closed at $16.39 after 21 trading sessions, up 36.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $16.38 | $16.54 | $16.23 | $16.39 | 402.57K |
| Aug 26, 2026 | $16.90 | $16.94 | $16.35 | $16.40 | 367.18K |
| Aug 25, 2026 | $16.90 | $17.125 | $16.80 | $16.92 | 503.72K |
| Aug 24, 2026 | $17.11 | $17.14 | $16.68 | $16.75 | 417.05K |
| Aug 21, 2026 | $16.84 | $17.15 | $16.60 | $17.14 | 509.06K |
| Aug 20, 2026 | $17.05 | $17.15 | $16.61 | $16.75 | 385.92K |
| Aug 19, 2026 | $17.14 | $17.34 | $16.8917 | $17.15 | 531.09K |
| Aug 18, 2026 | $16.95 | $17.17 | $16.62 | $16.86 | 481.6K |
| Aug 17, 2026 | $16.68 | $17.06 | $16.51 | $17.05 | 532.56K |
| Aug 14, 2026 | $17.30 | $17.40 | $16.675 | $16.73 | 529.52K |
| Aug 13, 2026 | $17.11 | $17.40 | $16.86 | $17.36 | 815.05K |
| Aug 12, 2026 | $17.10 | $17.28 | $16.63 | $17.11 | 774.67K |
| Aug 11, 2026 | $16.88 | $17.42 | $16.485 | $17.22 | 1.23M |
| Aug 10, 2026 | $15.00 | $16.69 | $15.00 | $16.67 | 1.48M |
| Aug 7, 2026 | $15.67 | $16.375 | $14.965 | $15.11 | 1.21M |
| Aug 6, 2026 | $14.03 | $15.62 | $14.00 | $15.47 | 2.99M |
| Aug 5, 2026 | $13.21 | $13.2492 | $12.43 | $12.63 | 433.02K |
| Aug 4, 2026 | $13.15 | $13.33 | $13.04 | $13.14 | 441.36K |
| Aug 3, 2026 | $12.35 | $13.08 | $12.35 | $13.04 | 579.88K |
| Jul 31, 2026 | $12.01 | $12.23 | $11.6928 | $12.22 | 372.15K |
| Jul 30, 2026 | $11.63 | $12.08 | $11.63 | $12.04 | 306.89K |
The latest Smart Investors Daily articles mentioning DCTH.
DCTH research
Company profile and research snapshot.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Feb 26, 2026 | BTIG | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 5, 2025 | Stephens & Co. | Overweight | — |
No generated briefing is available yet.
Yahoo · Aug 12, 2026
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Yahoo · Aug 11, 2026
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Yahoo · Aug 11, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SeekingAlpha · Aug 7, 2026
Delcath posted strong Q2 results; 2026 growth looks robust with milder Q3 seasonality and HEPZATO expansion optionality. Click here to read more about DCTH.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DCTH.
